№ files_lp_3_process_7_032889
File format: docx
Character count: 11609
File size: 240 KB
This directory provides a list of healthcare professionals and centers specializing in medical care for trans* individuals undergoing hormone replacement therapy and HIV-positive refugees.
Year:
2023
Region / City:
Austria
Theme:
Healthcare support for trans* individuals and HIV-positive refugees
Document type:
Directory
Organization:
Multiple healthcare providers
Author:
Not specified
Target audience:
Trans* individuals undergoing HRT, HIV-positive refugees
Period of validity:
Ongoing
Date of approval:
Not specified
Date of changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document type:
Supplementary tables
Study population:
HIV-positive (n=142) and HIV-negative (n=73) participants
Subgroup analysis:
HIV-negative participants (n=71 with pre-; n=73 with post- measurements)
Measured variables:
CD4 T cell phenotypes, CD8 T cell phenotypes, monocyte phenotypes
Phenotype categories:
Differentiation, Activation Profiles, Inflammation/Exhaustion Profiles, Senescence Profiles
Monocyte subsets:
Classical, Intermediate, Non-Classical
Pulmonary function measures:
FEV1, FVC, FEV1/FVC, DLCO
Statistical methods:
Two-sample t-test; linear regression models with adjustment for HBV infection, HCV infection, smoking pack-years, body-mass index, marijuana use, crack cocaine use, injection drug use, tuberculosis, pneumonia
Data presentation:
Median (IQR); standardized beta coefficients
Reference standards:
NHANES III predicted lung function values
Significance thresholds:
P < 0.05 with Bonferroni correction (P=0.05/112)
Country:
Nigeria
City / Region:
Port Harcourt, Rivers State
Research Location:
Rivers State University Teaching Hospital (RSUTH); University of Port Harcourt Teaching Hospital (UPTH)
Subject Area:
Hematology; Hemostasis; HIV/AIDS Research
Type of Document:
Scientific Research Article
Study Population:
Human Immunodeficiency Virus-Positive subjects aged 20–79 years
Sample Size:
150 participants
Study Groups:
First-line regimen (Abacavir Lamivudine Dolutegravir); Second-line regimen (Tenofovir Lamivudine Dolutegravir); Naïve HIV-positive control group
Medical Conditions Studied:
Human Immunodeficiency Virus (HIV); hematologic abnormalities; haemostatic abnormalities
Laboratory Methods:
Sysmex XP-300 Automated Haematology Analyzer; Enzyme Linked Immunosorbent Assay (ELISA); Prothrombin Time (PT); Activated Partial Thromboplastin Time (APTT)
Statistical Analysis:
Student’s independent t-test; Analysis of Variance (ANOVA); Microsoft Office Excel 2007; GraphPad Prism 6.2
Measured Parameters:
White blood cell count; lymphocyte count; haemoglobin; neutrophil-to-lymphocyte ratio; prothrombin time; activated partial thromboplastin time; D-dimer levels
Study Objective:
Assessment of hematologic and haemostatic profiles in HIV-positive subjects receiving different antiretroviral regimens
Keywords:
Hematologic; Haemostatic; Human Immunodeficiency Virus-Positive Subjects; Antiretroviral regimen; First-line; Second-line; Naïve
Year:
2023
Region / City:
England
Subject:
Hormone Replacement Therapy, NHS prescriptions
Document Type:
Guidance
Institution:
NHS
Author:
Not specified
Target Audience:
GPs, prescribers, pharmacists, pharmacy staff
Period of Validity:
Starting 1 April 2023
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Date form completed
Please tick if you have had or currently have any of the following:
Stroke/TIA, Heart Attack, Blood clot in your legs or lungs (DVT or PE), Family history of blood clots in leg or lung, Liver problems, Breast cancer, Family History of breast cancer, Endometrial Cancer, Not applicable
Year:
2025
Region / City:
HNY ICB
Topic:
Post-menopausal bleeding, Hormone Replacement Therapy
Document type:
Guideline
Organization / Institution:
HNY ICB Pathways Oversight Meeting
Author:
C BREWER (CONS GYNAECOLOGY)
Target audience:
Primary Care Practitioners, Gynaecologists, Nurse Practitioners in Gynaecology
Period of validity:
September 2025 - September 2028
Approval date:
26/02/2025
Date of last revision:
13/11/2025
Next review date:
September 2028
Date issued:
September 2025
Approved & Ratified by:
HNY ICB Pathways Oversight Meeting CG 5 Guideline & Audit Group
Date of meeting:
26/02/2025
Version:
1
Contextual description:
A clinical guideline outlining the management of patients with post-menopausal bleeding (PMB) or unscheduled bleeding on hormone replacement therapy (HRT), detailing referral pathways and risk factors.
Note:
Year
Subject:
Endocrinology, Hormone Action
Document Type:
Educational Activity
Institution:
Colorado State University
Target Audience:
Students, Educators
Year:
2023
Region / City:
Europe
Topic:
Access to medicines, hormones, healthcare for trans and gender-diverse people
Document Type:
Analytical study
Organ / Institution:
United Nations Office of the High Commissioner for Human Rights
Author:
Transgender Europe (TGEU), ILGA-Europe
Target Audience:
Policymakers, Human Rights Advocates, Health Professionals
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
N/A
Year:
Not specified
Region / City:
Not specified
Topic:
Thyroid hormone sensitivity, Type 2 Diabetes, Non-Diabetes
Document Type:
Supplementary Table
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
England
Subject:
Hormone Replacement Therapy, NHS prescriptions
Document Type:
Guidance
Institution:
NHS
Author:
Not specified
Target Audience:
GPs, prescribers, pharmacists, pharmacy staff
Period of Validity:
Starting 1 April 2023
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / City:
Harrogate, North Yorkshire
Topic:
Gender Dysphoria Care
Document Type:
Policy Statement
Organization:
The Spa Surgery
Author:
Dr D Ganesh, Dr S K L Hay, Mrs C Hedges, Dr S Peachey
Target Audience:
Patients with gender dysphoria
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Region / City:
Australia
Theme:
Pharmaceutical Benefits, Growth Hormone Treatment
Document Type:
Government Policy
Organization / Institution:
Services Australia
Author:
Not specified
Target Audience:
Healthcare professionals, medical prescribers
Period of validity:
Ongoing
Approval Date:
May 2025
Amendment Date:
Not specified
Related medical conditions:
Growth hormone deficiency, Prader-Willi syndrome
Eligibility:
Paediatric and adult patients with specific growth hormone deficiencies
Prescribing Criteria:
Paediatric endocrinologists, general paediatricians with consultation
Treatment Phases:
Initial treatment, continuing treatment, non-PBS to PBS subsidized
Application Process:
Online PBS Authorities system, written authority form
Authority Contact:
Services Australia, 1800 700 270
Year:
Not specified
Region / city:
Not specified
Topic:
Hormones, Human Physiology
Document type:
Educational Material
Author:
Not specified
Target audience:
High school students, biology learners
Period of validity:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2026
Region:
Laboratory study
Subject:
Male hormone levels and testicular structure
Document type:
Supplementary data tables
Institution:
Research laboratory
Experimental groups:
VC, BPS1, BPS2, BPS3
Measured hormones:
ACTH, FSH, GH, LH, TSH, cortisol, progesterone, testosterone, T3, T4
Statistical analysis:
Kruskal-Wallis test with Dunn’s multiple comparison
Sample size:
n = 5 per group for hormone profiling, n = 9 per group for stereology
Units:
pg/ml, ng/ml, mIU/ml, µIU/ml
Target tissue:
Testes
Exposure:
Bisphenol S, increasing doses
Parameters evaluated:
Hormone concentration, testis volume, germ epithelium volume, interstitial volume
Significance threshold:
p < 0.05
Year:
2024
Region / City:
Erbil
Topic:
Thyroid Hormones and Aging
Document Type:
Research Project
Institution:
Erbil Technica Medical Institute
Authors:
Dashne Dashte Zrar, Zhwan Hoshyar Hassan, Mardin Barzan Shukr, Gulala Salam Nadr
Target Audience:
Medical Researchers, Healthcare Professionals
Period of Action:
2024
Approval Date:
January 2024
Date of Changes:
N/A
Year:
2023
Study type:
Clinical trial, Phase II
Disease focus:
Hormone receptor-positive, HER2-negative breast cancer
Intervention:
Letrozole plus Alpelisib
Cohorts:
PIK3CA-mutant, PIK3CA-wild-type
Sample size:
83 patients
Authors:
Ingrid A. Mayer, Aleix Prat, Daniel Egle, et al.
Endpoints:
Objective response rate (ORR), pathological complete response (pCR), safety and adverse events
Methods:
PIK3CA mutation testing via cobas® PIK3CA Mutation Test and Oncomine™ Focus Assay
Data collection period:
Baseline through ≥24 weeks of treatment
Primary outcomes:
Tumor response rates, adverse event frequency and severity
Safety outcomes:
Rash, gastrointestinal toxicities, hyperglycemia, liver enzyme elevations, hematologic events
Target population:
Adults with hormone receptor-positive, HER2-negative breast cancer eligible for neoadjuvant therapy
Regulatory status:
Approved investigational study protocol
Context:
Clinical study report presenting supplementary methods, patient characteristics, treatment exposure, response rates, and adverse events for a Phase II randomized trial of letrozole plus alpelisib in hormone receptor-positive, HER2-negative breast cancer patients.
Year:
2023
Region / City:
United Kingdom
Topic:
Hormone replacement therapy, asthma, menopause
Document Type:
Research study
Organization / Institution:
University of Edinburgh, Asthma UK
Author:
Syed A Shah, Holly Tibble, Rebecca Pillinger, Susannah McLean, Dermot Ryan, Hilary Critchley, David Price, Catherine M Hawrylowicz, Colin R Simpson, Ireneous N Soyiri, Francis Appiagyei, Aziz Sheikh, Bright I Nwaru
Target Audience:
Researchers, healthcare professionals
Study Period:
1/1/2000 – 12/31/2016
Approval Date:
2023
Funding:
Asthma UK, Health Data Research UK
Conflicts of Interest:
No conflicts of interest declared
Methodology:
Longitudinal cohort study, multilevel Cox regression models
Conclusion Date:
2023
Year:
2026
Region / City:
Not specified
Topic:
Pediatric endocrinology, growth hormone therapy
Document Type:
Clinical trial information letter
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Parents and guardians of children with isolated growth hormone deficiency
Study Type:
Non-inferiority randomized controlled trial
Purpose:
To evaluate the final height outcomes in children with I-GHD after discontinuation vs continuation of GH therapy
Participation:
Voluntary
Method:
GH stimulation test
Year:
2026
Region / city:
Khorramabad, Iran
Topic:
Electrochemical sensing, Thyroid hormone (T4) measurement
Document type:
Research article
Organization:
Lorestan University
Author:
Abdollah Yari, Fatemeh Biranvand
Target audience:
Researchers, Chemists, Medical professionals
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A